Bills increase access to affordable drugs in the US and the Philippines

INICIO/Políticas y legislación | Posted 14/05/2021 post-comment0 Post your comment

In the opening months of 2021, a bill was proposed to make more biosimilars accessible to a greater proportion of the US state of Minnesota’s residents. In addition, a bill was passed in Wisconsin that will give pharmacists the ability to recommend cheaper drug options. And, in the Philippines, a bill has been filed to encourage the use of biosimilar drug products. 

Biological 143606710 V14J14ct

The Minnesota bill
In late February 2021, Jennifer Schultz (DFL-Duluth) and State Senator Carla Nelson (R-Rochester) sponsored a biosimilars bill in Minnesota. The aim of this is to broaden access to biosimilars by making it a requirement that health plans and pharmacy benefit managers cover all versions of biological agents, including biosimilars. The bill comes in response to payer policies that can reduce choices and force providers and patients to use more costly versions of a given biological. It is hoped that the bill would give every patient access to the most affordable and effective treatment options without compromising safety.

If the bill is successful, it is proposed to go live on 1 January 2022. It would be the first law of this kind to be enacted.

The Wisconsin bill
In Wisconsin, pharmacies were banned from offering patients cheaper drugs if they are not covered by their insurance plan. However, on 16 March 2021 a bill was passed to regulate pharmacy benefit managers in Wisconsin. It is hoped that this will stop pharmacy benefit managers from signing agreements with pharmacies that only allow pharmacists to recommend drugs covered by a person's insurance plan. The bill will ensure that pharmacy benefit managers are licensed and registered with the Office of the Commissioner of Insurance.

The Philippines bill
In the Philippines, Joey Salceda, the House Committee on Ways and Means chairperson and representative of Albay’s second district, has filed a bill to encourage use of biosimilar drug products. Salceda hopes that this Biosimilars bill (House Bill 9261) will improve access to biosimilars in the Philippines and make the public more aware of these cheaper alternative products. To do this, the bill will increase the range of choices for patients and healthcare providers. It will require the Secretary of Health to maintain a list of biosimilar products and their prices. It also mandates that the Secretary of Health educates and increases awareness of biosimilar products.

Related articles
Colorado to import drugs from Canada and beyond

Biden vows to protect Obamacare and increase reliance on quality generics

Generics and biosimilars can save Ireland Euros 1 billion in five years

Reasons and solutions for the high cost of Insulin in the US

Biosimilars substitution bill becomes law in South Dakota

LATIN AMERICAN FORUM – Coming soon!

To further enhance the objectives of GaBI in sharing information and knowledge that ensure policies supportive of safe biosimilars use, we are pleased to announce that we will be launching a new section on GaBI Online and GaBI Journal, the ‘Latin American Forum’ (in Spanish) featuring the latest news and updates on research and developments in generic and biosimilar medicines in Latin America.

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

 

LATIN AMERICAN FORUM – Próximamente!

Para fomentar los objetivos de GaBI sobre la difusión de información y conocimiento sobre las políticas de apoyo que garantizan el uso seguro de medicamentos biosimilares, nos complace anunciar el lanzamiento de una nueva sección en GaBI Online y GaBI Journal, el ‘Latin American Forum’ (en español), que presentará las últimas noticias y actualizaciones en investigación y desarrollo sobre medicamentos genéricos y biosimilares en Latinoamérica.

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
FDA publishes final Q&A on biosimilar development and the BPCI Act
Question-Fimea-V15E29
INICIO/Políticas y legislación Posted 15/10/2021
FDA voices concerns around drug patents and competition
Patent 1 V13E17
INICIO/Políticas y legislación Posted 08/10/2021
USA BIOSIM Act introduction
02 AA010638
INICIO/Políticas y legislación Posted 17/09/2021
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010